Thermo Fisher Scientific agreed to acquire clinical trial data firm Clario in a transaction reported at roughly $8.8–$9 billion to broaden its digital capabilities in clinical research. Clario supplies software and services that collect and analyze clinical trial endpoint data; Thermo Fisher plans to integrate the business into its Laboratory Products and Biopharma Services segment. The acquisition pairs Clario’s trial data platform with Thermo Fisher’s existing CRO assets and is positioned to accelerate end-to-end digital offerings for sponsors. Analysts see the deal as complementary to Thermo Fisher’s prior acquisition of PPD and a strategic push to capture more of the trial-services value chain.